A Clinical Study on the Safety and Efficacy of Chimeric Antigen Receptor T-cell (CART) in the Treatment of Solid Tumors

NCT ID: NCT05745454

Last Updated: 2023-02-27

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 12 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-02-28
• Study Completion Date: 2025-12-31

Brief Summary

This is a single-arm, investigator-initiated exploratory study.The study is designed to evaluate the safety and the tolerability of HER2-E-CART cells for the treatment of patients with HER2-positive, refractory advanced solid tumors in three dose groups: low, medium and high.

Detailed Description

This study was a one-arm,investigator-initiated exploratory study. According to the "3+3" principle, three dose groups with increasing dose were set up, namely low, medium and high dose groups, with separate cell counts. A total of 9-12 subjects were enrolled in the group and given intravenous infusion. Dose-limited toxicity was observed from the beginning of preconditioning to 28 days after CAR T infusion.

Conditions

Solid Tumor

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

HER2-E-CART cells

HER2-E-CART cells were intravenously transfused and followed up to 2 years after the last cell transfusion

Group Type: EXPERIMENTAL

HER2-E-CART cells

Intervention Type: BIOLOGICAL

E-CAR-T is a novel second-generation CAR-T product targeting HER2 protein

Interventions

HER2-E-CART cells

E-CAR-T is a novel second-generation CAR-T product targeting HER2 protein

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

1. Voluntarily signed an informed consent form and were able to complete the study procedures and follow-up examinations and treatment

2. Age ≥ 18 years and ≤ 70 years, regardless of gender

3. Weight > 40 kg

4. Eastern Cooperative Oncology Group (ECOG) physical status score of 0 to 1

5. Patients with refractory advanced solid tumors who have failed or are intolerant of existing standard regimens or whose patients have refused standard regimens

6. The presence of at least one measurable lesion according to Response Evaluation Criteria In Solid Tumors 1.1 criteria

7. With good organ function

8. Positive HER2 cell membrane expression

9. Women of childbearing potential must have a pregnancy test with negative results within 7 days prior to initiation of treatment

Exclusion Criteria

1. Any systemic antitumor therapy within 2 weeks prior to the single blood collection

2. History of organ transplantation

3. Pregnant or lactating women

4. Uncontrolled infectious disease, such as baseline Hepatitis B Virus DNA ≥ 1000 IU/ml, anti-HIV positive, Hepatitis C Virus-RNA positive

5. Other clinically significant active infections

6. Other active malignancies within the previous 5 years, such as basal or squamous skin cancer, superficial bladder cancer, or in situ breast cancer that has been completely cured and does not require follow-up treatment subjects are not included

7. Patients with severe autoimmune or immunodeficiency diseases, such as subjects with a confirmed diagnosis of a severe autoimmune disease requiring systemic immunosuppressive (steroid) therapy for a prolonged period of time (more than 2 months) or with immune-mediated symptomatic diseases, including ulcerative colitis, Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus (SLE), autoimmune vasculitis (e.g., Wegener's granulomatosis), etc

8. Subjects with known severe allergic reactions to pretreatment drugs such as injectable cyclophosphamide, injectable paclitaxel (albumin-bound), or CAR-T cell preparations including adjuvants, dimethylsulfoxide

9. Any unstable systemic disease: including but not limited to unstable angina pectoris, cerebrovascular accident or transient ischemia (within 6 months prior to screening), myocardial infarction (within 6 months prior to screening), New York Heart Association (NYHA) classification ≥ Class III congestive heart failure, severe arrhythmias poorly controlled by medications, liver, kidney or metabolic disease, and hypertension uncontrolled by standard therapy 10

10. Those with active bleeding, thrombotic disorders requiring treatment

11. Patients with pericardial, thoracic, or abdominal effusions requiring clinical management or intervention

12. The presence of known or suspected brain metastases, including central nervous system and spinal cord compressions or meningeal metastases

13. Subjects undergoing treatment with systemic steroids or steroid inhalers

14. Subjects with any psychiatric disorder, including dementia, altered mental status, that may interfere with informed consent and understanding of relevant questionnaires

15. Having participated in another clinical trial within the previous 30 days

16. Have received a live or attenuated vaccine within 4 weeks prior to pretreatment

17. Those who have been judged by the investigator to have a serious uncontrollable disease or have other conditions that may interfere with receiving treatment in this study and are considered unsuitable

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

su haichuan

OTHER

Sponsor Role: lead

Responsible Party

su haichuan

Head of Department

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Haichuan Su, Doctor

Role: PRINCIPAL_INVESTIGATOR

The Second Affiliated Hospital of PLA Air Force Medical University

Central Contacts

Haichuan Su, Doctor

Role: CONTACT

cntdgcp@163.com

18629190366

Song Yang, Doctor

Role: CONTACT

songyang212212@163.com

13991108870

Other Identifiers

HER2-E-CART

Identifier Type: -

Identifier Source: org_study_id